Board Ruth E, Thistlethwaite Fiona C, Hawkins Robert E
Cancer Research UK Department Medical Oncology, Christie Hospital, Manchester M20 4BX, UK.
Cancer Treat Rev. 2007 Feb;33(1):1-8. doi: 10.1016/j.ctrv.2006.08.003. Epub 2006 Oct 27.
Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.
转移性肾细胞癌预后较差，且对传统化疗药物耐药。大多数肿瘤与冯·希佩尔-林道基因失活及随后包括血管内皮生长因子（VEGF）在内的促血管生成因子过度表达有关。针对这些通路的药物已在肾细胞癌中进行了临床试验，结果令人鼓舞。这类疗法必将彻底改变肾细胞癌的治疗方式，本综述概述了近期临床试验的证据，这些试验研究了其中最有前景的药物。
